Drugs / INT-2150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03509831 | Nov 2017 → Jan 2018 | gastritis | Kukje Pharma | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INT-2150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03509831 ↗ |
| Route | Oral | “After Oral Administration” NCT03509831 ↗ |